scholarly journals Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer

2020 ◽  
Vol 37 (6) ◽  
pp. 649-656
Author(s):  
Hannah Voß ◽  
Marcus Wurlitzer ◽  
Daniel J. Smit ◽  
Florian Ewald ◽  
Malik Alawi ◽  
...  

AbstractColorectal cancer (CRC) patients suffer from the second highest mortality among all cancer entities. In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed. Metastatic colorectal cancer is associated with poor overall survival and limited treatment options. Even after successful surgical resection of the primary tumor, metachronous liver metastases occur in one out of eight cases. The only available curative intended treatment is hepatic resection, but metachronous CRLM frequently recur after approximately 1 year. In this study, we performed a proteome analysis of three recurrent liver metastases of a single CRC patient by mass spectrometry. Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred consecutively after 9, 21 and 31 months. We identified a set of 1132 proteins expressed in the three metachronous CRLM, of which 481 were differentially regulated, including 81 proteins that were associated with the extracellular matrix (ECM). 56 ECM associated proteins were identified as upregulated in the third metastasis, 26 (46%) of which were previously described as negative prognostic markers in CRC, including tenascin C, nidogen 1, fibulin 1 and vitronectin. These data may reflect an ascending trend of malignancy from the first to the third metachronous colorectal cancer liver metastasis. Additionally, the results indicate different ECM phenotypes for recurrent metachronous metastasis, associated with different grades of malignancy and highlights the importance of individual analysis of molecular features in different, consecutive metastatic events in a single patient.

2004 ◽  
Vol 106 (s50) ◽  
pp. 2P-2P
Author(s):  
J.A. Conti ◽  
R.C. Benyon ◽  
J.N. Primrose ◽  
J.P. Iredale

1987 ◽  
Vol 205 (3) ◽  
pp. 264-270 ◽  
Author(s):  
FEDERICO BOZZETTI ◽  
ROBERTO DOCI ◽  
PAOLA BIGNAMI ◽  
ALBERTO MORABITO ◽  
LEANDRO GENNARI

2016 ◽  
Vol 12 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Mashaal Dhir ◽  
Aaron R. Sasson

Surgical resection remains one of the major curative treatment options available to patients with colorectal liver metastases. Surgery and chemotherapy form the backbone of the treatment in patients with colorectal liver metastases. With more effective chemotherapy regimens being available, the optimal timing and sequencing of treatments are important. A multidisciplinary approach with the involvement of medical oncologists and surgical oncologists from the beginning is crucial. Identification of the clinical and molecular prognostic factors may help personalize the treatment approaches for these patients. This article provides an overview of the surgical management of colorectal liver metastases.


2020 ◽  
pp. 1-6
Author(s):  
Zhiming Zhao ◽  
Mengyang Li ◽  
Xianglong Tan ◽  
Zhiming Zhao

The liver is the most common site of metastasis in colorectal cancer (CRC). Treatment of liver metastases determines the prognosis of patients with CRC. Tremendous progress has been made during the last two decades, which has greatly improved the overall survival of CRC patients. Currently, various treatment options are available, including hepatectomy, liver transplantation, local regional therapy, chemotherapy, targeted therapy, and immune therapy, inevitably leading to some controversies on treatment indications and selection of treatment strategy. Here, we reviewed the existing approaches to treat colorectal cancer liver metastases, with the aim of examining several crucial questions regarding surgical resection, liver transplantation, and medical treatment in clinical practice.


Sign in / Sign up

Export Citation Format

Share Document